Sutherland Leslie C, Thibault Philippe, Durand Mathieu, Lapointe Elvy, Knee Jose M, Beauvais Ariane, Kalatskaya Irina, Hunt Sarah C, Loiselle Julie J, Roy Justin G, Tessier Sarah J, Ybazeta Gustavo, Stein Lincoln, Kothary Rashmi, Klinck Roscoe, Chabot Benoit
Health Sciences North Research Institute, Sudbury, ON, P3E 5J1, Canada.
Biomolecular Sciences Program, Laurentian University, Sudbury, ON, P3E 2C6, Canada.
BMC Mol Biol. 2017 Jul 20;18(1):19. doi: 10.1186/s12867-017-0096-x.
RBM10 is an RNA binding protein involved in message stabilization and alternative splicing regulation. The objective of the research described herein was to identify novel targets of RBM10-regulated splicing. To accomplish this, we downregulated RBM10 in human cell lines, using small interfering RNAs, then monitored alternative splicing, using a reverse transcription-PCR screening platform.
RBM10 knockdown (KD) provoked alterations in splicing events in 10-20% of the pre-mRNAs, most of which had not been previously identified as RBM10 targets. Hierarchical clustering of the genes affected by RBM10 KD revealed good conservation of alternative exon inclusion or exclusion across cell lines. Pathway annotation showed RAS signaling to be most affected by RBM10 KD. Of particular interest was the finding that splicing of SMN pre-mRNA, encoding the survival of motor neuron (SMN) protein, was influenced by RBM10 KD. Inhibition of RBM10 resulted in preferential expression of the full-length, exon 7 retaining, SMN transcript in four cancer cell lines and one normal skin fibroblast cell line. SMN protein is expressed from two genes, SMN1 and SMN2, but the SMN1 gene is homozygously disrupted in people with spinal muscular atrophy; as a consequence, all of the SMN that is expressed in people with this disease is from the SMN2 gene. Expression analyses using primary fibroblasts from control, carrier and spinal muscle atrophy donors demonstrated that RBM10 KD resulted in preferential expression of the full-length, exon 7 retaining, SMN2 transcript. At the protein level, upregulation of the full-length SMN2 was also observed. Re-expression of RBM10, in a stable RBM10 KD cancer cell line, correlated with a reversion of the KD effect, demonstrating specificity.
Our work has not only expanded the number of pre-mRNA targets for RBM10, but identified RBM10 as a novel regulator of SMN2 alternative inclusion.
RBM10是一种RNA结合蛋白,参与信息稳定和可变剪接调控。本文所述研究的目的是鉴定RBM10调控剪接的新靶点。为实现这一目标,我们使用小干扰RNA在人细胞系中下调RBM10,然后使用逆转录-聚合酶链反应筛选平台监测可变剪接。
RBM10基因敲低(KD)导致10%-20%的前体mRNA的剪接事件发生改变,其中大多数此前未被鉴定为RBM10靶点。受RBM10 KD影响的基因的层次聚类显示,可变外显子包含或排除在各细胞系间具有良好的保守性。通路注释显示RAS信号传导受RBM10 KD影响最大。特别值得关注的是,编码运动神经元存活蛋白(SMN)的SMN前体mRNA的剪接受RBM10 KD影响。RBM10的抑制导致四种癌细胞系和一种正常皮肤成纤维细胞系中全长、保留外显子7的SMN转录本的优先表达。SMN蛋白由SMN1和SMN2两个基因表达,但脊髓性肌萎缩症患者的SMN1基因纯合缺失;因此,患有这种疾病的人所表达的所有SMN均来自SMN2基因。使用来自对照、携带者和脊髓性肌萎缩症供体的原代成纤维细胞进行的表达分析表明,RBM10 KD导致全长、保留外显子7的SMN2转录本的优先表达。在蛋白质水平,也观察到全长SMN2上调。在稳定的RBM10 KD癌细胞系中重新表达RBM10,与KD效应的逆转相关,证明了特异性。
我们的工作不仅增加了RBM10的前体mRNA靶点数量,还将RBM10鉴定为SMN2可变包含的新型调节因子。